From Wikipedia, the free encyclopedia
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
Targetinterferon gamma
Clinical data
ATC code
  • none
CAS Number
  • none
Chemical and physical data
Molar massca. 150 kg/mol
 ☒NcheckY (what is this?)  (verify)

Fontolizumab (planned trade name HuZAF) is a humanized monoclonal antibody[1] and an immunosuppressive drug for the treatment of auto-immune diseases like Crohn's disease.[2] A phase II clinical trial investigating the use for rheumatoid arthritis was terminated because the first phase did not meet the endpoint.[3]


  1. ^ Statement On A Nonproprietary Name Adopted By The Usan Council - Fontolizumab, American Medical Association.
  2. ^ Reinisch W, de Villiers W, Bene L, Simon L, Rácz I, Katz S, et al. (February 2010). "Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study". Inflammatory Bowel Diseases. 16 (2): 233–42. doi:10.1002/ibd.21038. PMID 19637334. S2CID 25337474.
  3. ^ Clinical trial number NCT00281294 for "A Phase 2 Study to Evaluate the Safety, Tolerability, and Activity of Fontolizumab in Subjects With Active Rheumatoid Arthritis" at